Mode
Text Size
Log in / Sign up
N/A Completed N=149 Randomized Triple-blind Treatment

Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)

Source: ClinicalTrials.gov NCT03168867 ↗
Enrolled (actual)
149
Serious AEs
35.6%
Results posted
Apr 2023
Primary outcomePrimary: Glycemic Control — 11.51; 11.48; 11.55; 11.14 percentage of glycosylated hemoglobin — p=<.05

Summary

The purpose of the study is to conduct a multicenter, randomized effectiveness trial of The 3Ms. The proposed study will use an effectiveness-implementation "Hybrid 1" design. In this design, the primary goal is to determine whether an intervention works in a real-world setting, but the design also answers secondary questions such as the relationship between treatment dose and treatment outcome and what factors affect the actual delivery of the intervention in the clinics (staff burden, workflow interference etc).

Outcome Measures

OutcomeResultp-value
PRIMARY
Glycemic Control
11.51; 11.48; 11.55; 11.14; 11.47; 11.09 <.05 sig
SECONDARY
Regimen Adherence (Objective)
SECONDARY
Diabetes Management (Self-reported)
SECONDARY
Parental Monitoring of Diabetes Care (Self-reported)
SECONDARY
Diabetes- Specific Family Functioning (Self-reported)
SECONDARY
Adolescent Depression (Self-reported)
SECONDARY
Executive Functioning (Self-reported)
SECONDARY
Cost Analysis (Self-reported)
SECONDARY
Diabetes Emotional Distress (Self-reported)
SECONDARY
Household Chaos (Self-reported)

Eligibility Criteria

Inclusion Criteria

  • Age: 10 years 0 months - 15 years, 11 months
  • Diagnosed with Type 1 diabetes
  • Diagnosed for at least 6 months
  • African American
  • Residence within 30 miles of a recruitment site (Children's Hospital of Michigan, Ann and Robert H. Lurie Children's Hospital of Chicago, Children's Hospital University of Illinois, or La Rabida Children's Hospital of Chicago)
  • Primary caregiver willing to participate

Exclusion Criteria

  • Mental health conditions that might compromise data integrity (e.g., developmental delay, schizophrenia, psychosis, current suicidality, homicidality)
  • Co-morbid medical condition resulting in atypical diabetes management (e.g., cystic fibrosis)
  • Inability to speak or read English
  • Child is in out-of-home placement
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03168867). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search